Drug Delivery - Innovations, trends, and their impact on pharma

News provided by

Mar 09, 2016, 02:14 ET

LONDON, March 9, 2016 /PRNewswire/ -- Why you need Drug Delivery - Innovations, trends, and their impact on pharma

Revolutionary changes are disrupting the status quo simply through developments in the way drugs are given to patients. In a rapidly evolving field, drug delivery systems are offering growth opportunities and solutions – as well as presenting difficulties – as the range of choices grows.

To make sure you don't get left behind you need to understand what is happening at the cutting edge from experts innovating and leading the way through the technological and regulatory minefield. See how companies like Sanofi, Surefire Medical and Invion among other market leaders explain how they see the market and how they are dealing with the challenges.

Top Takeaways:

Change is accelerating. There's a wide range of new products at late-stage development, 200+ partnership deals are signed each year and device companies are now entering the market directly
Reliance on delivery mechanisms is increasing as health economics requirements on efficacy and cost-effectiveness multiply
Significant delivery mechanism opportunities still exist with the potential to solve unmet needs with new formulations
Drug combinations offer risks and rewards – the promise of innovative formulas is potentially hampered by technology and regulation
Product franchises are protected by differentiating products and by extending a profitable drug's lifecycle
Opportunities are growing in new markets as the Far East opens up and China expands healthcare to the wider population

Key Issues Explored

Key drivers and how devices are transforming the market including oral medicines, inhalers, injectable devices, patches, subdermal implants, neurostimulation and smart devices
The challenges faced in choosing and developing the right delivery system and formulations, looking at biopharmaceuticals, biologics, excipients, large and small molecules, peptides, proteins and biosimilars
Hurdles to commercialisation globally – how companies are evolving strategies to deal with local regulatory issues for global products
Improving patient compliance with better outcomes and the potential for home-based care offered by some systems
The value of overcoming technical challenges before clinical trials begin
The cost-benefit considerations of different development models including outsourcing, partnerships and internal development.
The impact of health economics on innovation in the drug delivery market, reimbursement concerns and access issues

Who needs this report?

Presidents and VPs of product development – to see the drugs and devices in the pipeline and the potential opportunities and risks involved
Business development directors – to get support and improve and refine strategic direction and decisions
Device development team managers – to see expansion possibilities and the current state of the competitive market
Delivery and formulation specialists – to analyse current best practice
Manufacturers of devices – to see the top drug delivery partnerships and get an overview of growth prospects
Insurers and payers – to gain insights into the value of more effective delivery mechanisms to ensure the best use of limited resources
Big data companies and electronic health companies – to see current and future developments in connected devices

Contributors

Director, Drug Delivery Technologies, European Pharma Company,
Vice President, Medical Device Development, Global pharma Company
Igor Gonda: President & CEO, Aradigm Corporation [Linkedin]
Jeff Macdonald: Senior Director, Corporate Communications, Acorda Therapeutics
Seth Yakatan: CSO, Vice President of Business Development, Invion Group
Director, Corporate Development, Respiratory Product Development Company
Director, Pharmaceutical Sciences, Respiratory Product Development Company Douglas Marenzi: CEO, PHC Technologies
David Urquhart: Business Development, PHC Technologies
Morten Nielsen: CEO, Medicom Innovation Partner
Frédéric Gabriel: CSO and General Manager, Haselmeier
Jim Chomas Ph.D: President and CEO, Surefire Medical
Norman Weldon: Chairman, SureFire Medical
Julian Chick, Ph.D: COO, Admedus Ltd
JP Errico, Ph.D: CEO, electroCore Medical

Download the full report: https://www.reportbuyer.com/product/3607553/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com